steven hoerter  agios pharmaceuticals inc  zoominfocom   steven l hoerter  boulder co  intelius sign in we found steven l hoerter in boulder co steven l hoerter intelius found that steven l hoerter is a male between  and  years old from boulder co we have connected them to  addresses  phones and  relatives or associates also known as steve hoerter get report now age steven l hoerter is in his s steven has lived in boulder co winter park fl indianapolis in stevens relatives robert hoerter trust hoerter alexander hoerter orpha platt steven l hoerter zodiac signlibra gendermale professional status senior vice president commercial at clovis oncology inc get report now want to know more about steven get a comprehensive background report find full phone numbers and other contact information when available all from billions of available public records continue below for more details about steven or use our people search engine to find others get background check on steven l hoerter get a criminal check on steven l hoerter get a public record report on steven l hoerter get a people search report on steven l hoerter steven l hoerters contact information known cities lived in find out where steven l hoerter has lived as well as steven l hoerters phone numbers and email addresses steven l hoerter has lived in  states colorado address for steven l hoerter   s boulder co has lived in boulder co winter park fl get full address report phone numbers associated with steven l hoerter    chapel hill nc    boulder co    wellesley hills ma get full phone report email addresses associated with steven l hoerter hecom srcom srcom get email report steven l hoerters professional information information regarding steven l hoerters professional history find out previous places steven l hoerter has worked as well as dates employed the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act steven l hoerter has worked at  places company clovis oncology inc title senior vice president commercial company clovis oncology inc title senior vice president commercial steven l hoerters experience title senior vice president commercial company clovis oncology inc job details company size  mil to less than  mil  employee range  to less than  title senior vice president commercial company clovis oncology inc job details company size  mil to less than  mil  employee range  to less than  additional professional information on steven l hoerter see steven l hoerters linkedin profile steven l hoerters social network and potential email matches find out potential social network profiles and potential email usernamed for steven l hoerter steven l hoerters known social networks and potential email matches find all of steven l hoerters social network profiles get full report search social networks including facebook linkedin myspace google twitter yahoo jigsaw zoominfo and more potential email matches steven hoerter username matches stevenhoerter hoertersteven stevenhoerter hoertersteven stevenhoerter hoertersteven stevenhoerter hoertersteven shoerter popular email services gmailcom aolcom yahoocom comcastnet hotmailcom msncom rocketmailcom attnet sbcglobalnet ymailcom facebookcom mailcom bellsouthnet livecom earthlinknet coxnet prodigynet mecom peoplepccom junocom rediffmailcom mindspringcom comcastcom charternet outlookcom all trademarks product names company names or logos on this page are the property of their respective owners related people searches s hoerter intelius is a leading provider of public data about people and their connections to others intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fair credit reporting act fcra this site should not be used to determine an individual’s eligibility for credit insurance employment housing or any other purpose covered by the fcra for employment or tenant screening services please visit our partner talentwise about us site map about our reports blog help contact us   –  peopleconnect inc dba intelius all rights reserved privacy policy  updated terms of service  updated what is the fcra the fair credit reporting act fcra is a federal law that promotes the accuracy fairness and privacy of information in the files of consumer reporting agencies intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fcra intelius reports cannot be used for background checks related to consumer credit insurance employment housing or any other purpose prohibited under the fcra you may not use any information obtained from intelius for any purpose covered by the fcra find out more about the fcra here clvs steven l hoerter insider trades for clovis oncology inc bulletin investor alert expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close clovis oncology inc nasdaq clvs go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus clovis oncology inc after hours  quotes are delayed by  min jul    pm clvs quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   insider activity individual steven l hoerter transactions date shares transaction value     disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share  copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives mr patrick j mahaffy president chief executive officer  director mr daniel w muehl svpfinance chief financial  accounting officer dr lindsey rolfe chief medical officer  executive vpclinical ms gillian c iversread chief regulatory officer  executive vp mr corwin dale hooks chief commercial officer  senior vice president mr paul gross chief compliance officer svp  general counsel ms breanna burkart headinvestor relations ms anna sussman investor relations contact ms ann bozeman senior vice presidenthuman resources dr michael james barrett chairman dr jim c blair independent director mr brian g atwood independent director dr thorlef spickschen independent director mr edward j mckinley independent director mr paul h klingenstein independent director dr keith t flaherty independent director ms ginger l graham independent director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  am edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pwall street isn’t ready for a point tumble in the dow industrials pbarrons buzz robo  facebook and twitter trading on news pa wild week in washington pthe dark side of cruises pthe highest paid athletes in the world in one chart poj simpson made over  while in prison and won’t have to give any of it to the goldman family p trump to police dont be too nice phere are  coworkers you should avoid like the plague — especially in meetings ptop  most annoying people you may want to unfriend on facebook pthis is one person you should never unfriend on facebook p horrible ways typos could alter the course of your life ppaint your bathroom this color and boost your home’s selling price by  pamericans’ new badge of honor ‘i was blocked by a celebrity’ p weird things i found out about america in my first  hours pbeyond tesla  stocks driving the autonomous car revolution pthese  highly taxed companies need congress to finally act on tax reform pwatch out ‘kids’ are making the most money in this stock market p real ways for millennials to save money not by brownbagging and skipping starbucks p‘game of thrones’ this computer model predicts who will be killed off — or survive pthis basic balanced index fund is beating the hedge fund averages loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  steven hoerter agios pharmaceuticals inc profile  biography  bloomberg feedback steven hoerter chief commercial officer agios pharmaceuticals inc career history chief commercial officer agios pharmaceuticals inc present exec vpchief commercial ofcr clovis oncology inc unknown gen mgrheadmgmt center hoffmannla roche  various positions genentech inc  senior vpcommercial clovis oncology inc unknown chiron corp former various positions eli lilly  co former show more website wwwagioscom corporate information address  sidney street cambridge ma  united states phone  fax  web url wwwagioscom from the web personal information education bucknell university bachelors degree purdue university masters degree management tilburg university mba show more memberships board memberships ignyta inc board member present sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data steven l hoerter  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in steven l hoerter chief commercial officer at agios pharmaceuticals inc view full profile are you steven l hoerter claim your profile   sign up for equilar atlas and view steven l hoerters full profile with equilar atlas you can identify corporate executives in steven l hoerters network and community follow changes in steven l hoerters employment and moneyinmotion connect with steven l hoerter through your network of contacts steven l hoerters executive work history current chief commercial officer agios pharmaceuticals inc board member ignyta inc past to view steven l hoerters complete executive work history sign up now age      steven l hoerters biography steve hoerter joined our board of directors in december  mr hoerter currently serves as chief commercial officer of agios pharmaceuticals inc a position he has held since february  and has more than twenty years of global pharmaceutical and biotechnology experience previously having served as executive vice president and chief commercial officer at clovis oncology inc there mr hoerter built and led the global commercial organization that developed gotomarket strategies for two oncology therapies before joining clovis in  he was general manager and management center head at roche for the subsaharan africa and indian  read more steve hoerter joined our board of directors in december  mr hoerter currently serves as chief commercial officer of agios pharmaceuticals inc a position he has held since february  and has more than twenty years of global pharmaceutical and biotechnology experience previously having served as executive vice president and chief commercial officer at clovis oncology inc there mr hoerter built and led the global commercial organization that developed gotomarket strategies for two oncology therapies before joining clovis in  he was general manager and management center head at roche for the subsaharan africa and indian ocean region from  to  mr hoerter held a variety of positions at genentech inc including serving on the senior leadership team for genentechs biooncology business as senior director pipeline development and commercial operations prior to that mr hoerter held commercial roles at chiron corporation and eli lilly and company in the us europe and africa mr hoerter received a ba in russian and political science from bucknell university an mba from tilburg university and an ms in management from purdue university we believe that mr hoerter adds value to our board of directors based on his senior management experience in the pharmaceutical and biotechnology industry with expertise in drug development and commercialization and other aspects of our industry source ignyta inc on    sign up for equilar atlas and view steven l hoerters full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like steven l hoerter more specifically youll be able to identify corporate executives in steven l hoerters network and community follow changes in steven l hoerters employment and moneyinmotion connect with steven l hoerter through your network of conections view full profile   search for over  executive profiles bio example steven l hoerter steven l hoerters connections  sign up now to view steven l hoerters  connections » james c blair former board member clovis oncology inc marc tessierlavigne scientific advisor agios pharmaceuticals inc keith t flaherty board member loxo oncology inc james l freddo former senior vice president drug development and chief medical officer anadys pharmaceuticals james bristol board member ignyta inc douglas g cole board member editas medicine inc erle t mast former executive vice president and chief financial officer clovis oncology inc patrick j mahaffy dir president and chief executive officer clovis oncology inc zachary hornby chief operating officer ignyta inc jacob m chacko chief financial officer ignyta inc popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith carl g annessa evp and coo hornbeck offshore services inc elon r musk ceo and chairman tesla michael c montgomery board member nmi holdings inc × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login ï¿½  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   ignyta appoints steven l hoerter chief commercial officer of agios pharmaceuticals inc to board of directors  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street ignyta appoints steven l hoerter chief commercial officer of agios pharmaceuticals inc to board of directors business wire dec    am est ignyta inc nasdaqrxdx  a biotechnology company focused on precision medicine in oncology today announced the appointment of mr steven l hoerter to its board of directors effective december   mr hoerter will serve as an independent director as well as a member of the nominating and corporate governance committee the appointment increases the number of ignyta directors from five to six steves extensive background in commercial strategy and operations complements the skillset of our existing board of directors very nicely and we are thrilled to welcome him to ignytas board said jonathan lim md chairman and ceo of ignyta we expect that his broad experience launching new oncology medicines will be an invaluable resource as ignyta seeks to transition into a fully integrated commercial organization mr hoerter has served as chief commercial officer of agios pharmaceuticals inc since february  and has more than  years of global pharmaceutical and biotechnology experience previously having served as executive vice president and chief commercial officer at clovis oncology inc there mr hoerter built and led the global commercial organization that developed gotomarket strategies for two oncology therapies before joining clovis in  he was general manager and management center head at roche for the subsaharan africa and indian ocean region from  to  mr hoerter held a variety of positions at genentech inc including serving on the senior leadership team for genentechs biooncology business as senior director pipeline development and commercial operations prior to that mr hoerter held commercial roles at chiron corporation and eli lilly and company in the us europe and africa mr hoerter received his ba from bucknell university mba from tilburg university and ms in management from purdue university mr hoerter commented im excited by ignytas robust precision oncology pipeline its strong team and outstanding commitment to helping patients with cancer i look forward to helping guide ignyta as it advances towards commercialization of its first product candidate if you liked this article you might like loxo oncology aims for genetic mutation cancer drug approval in  the loxo phase ii basket study of larotrectinib is expected to complete patient enrollment in early  and report results in the second half of the year adam feuerstein dec    am est  breakout stocks under  set to soar these under stocks are within range of triggering breakout trades roberto pedone aug    am edt  stocks under  making big moves toward big profits when a stock makes a largepercentage move it is often just the start of a new major trend  a trend that can lead to huge profits roberto pedone may    am edt loxo cancer drug targets gene mutation with durable responses in early study six patients all with trk fusion cancers unresponsive to current therapies reported tumor shrinkage following treatment with loxos drug loxo adam feuerstein apr    pm edt trending tesla headlines this lineup of  amazing new cars for  ftc seen as set to block rite aid deal  secrets tesla doesnt want to admit ahead of its big model  party amazon alphabet and a gop failure on healthcare heres where wall street stands teslas model  arrives very soon  heres everything you need to know about this overhyped ride advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers ignyta appoints steven l hoerter chief commercial officer of agios pharmaceuticals inc to board of directors  firstword medtech login  subscribe saturday july   get unlimited medtech plus subscriptions for one low fixed rate with a firstword medtech country licenseclick here for more details home my newsall my news my companywatch my conditionwatch my marketsegmentwatch my medicalmeetingwatch my productwatch my regulatorywatch all newsexplore latest news all company news all condition news all medical meeting news all product news all market segment news all regulatory market and agency news all therapeutic category news most popularmost popular in the last  hours most popular in the last  days most popular in the last  days storywatchduodenoscope reprocessing in focus emerging markets latest earnings reports pharma alliances product approvals and certifications us vaginalmesh product lawsuits where health meets tech servicesmobile search twitter rss podcasts radio ignyta appoints steven l hoerter chief commercial officer of agios pharmaceuticals inc to board of directors ref business wire december th  tags corporate affairs ivds agios pharmaceuticals ignyta tweet email print san diegobusiness wire ignyta inc nasdaqrxdxa biotechnology company focused on precision medicine in oncology today announced the appointment of mr steven l hoerter to its board of directors effective december   mr hoerter will serve as an independent director as well as a member of the nominating and corporate governance committee the appointment increases the number of ignyta directors from five to six steves extensive background in commercial strategy and operations complements the skillset of our existing board of directors very nicely and we are thrilled to welcome him to ignytas board said jonathan lim md chairman and ceo of ignyta we expect that his broad experience launching new oncology medicines will be an invaluable resource as ignyta seeks to transition into a fully integrated commercial organization mr hoerter has served as chief commercial officer of agios pharmaceuticals inc since february  and has more than  years of global pharmaceutical and biotechnology experience previously having served as executive vice president and chief commercial officer at clovis oncology inc there mr hoerter built and led the global commercial organization that developed gotomarket strategies for two oncology therapies before joining clovis in  he was general manager and management center head at roche for the subsaharan africa and indian ocean region from  to  mr hoerter held a variety of positions at genentech inc including serving on the senior leadership team for genentechs biooncology business as senior director pipeline development and commercial operations prior to that mr hoerter held commercial roles at chiron corporation and eli lilly and company in the us europe and africa mr hoerter received his ba from bucknell university mba from tilburg university and ms in management from purdue university mr hoerter commented im excited by ignytas robust precision oncology pipeline its strong team and outstanding commitment to helping patients with cancer i look forward to helping guide ignyta as it advances towards commercialization of its first product candidate about ignyta inc blazing a new future for patients with cancer™ at ignyta we work tirelessly on behalf of patients with cancer to offer potentially lifesaving precisely targeted therapeutics rx guided by companion diagnostic dx tests our integrated rxdx strategy allows us to enter uncharted territory illuminating the molecular drivers of cancer and quickly advancing treatments to address them this approach embraces even those patients with the rarest cancers who have the highest unmet need and who may otherwise not have access to effective treatment options with our pipeline of potentially firstinclass and bestinclass precision medicines we are pursuing the ultimate goal of not just shrinking tumors but eradicating cancer relapse and recurrence in precisely defined patient populations for more information please visit wwwignytacom forwardlooking statements this press release contains forwardlooking statements about ignyta as that term is defined in section a of the securities act of  and section e of the securities exchange act of  statements in this press release that are not purely historical are forwardlooking statements such forwardlooking statements include among other things references to mr hoerters potential contributions and the development of ignytas product candidates actual results could differ from those projected in any forwardlooking statements due to numerous factors such factors include among others the inherent uncertainties associated with developing new products or technologies and operating as a development stage company ignytas ability to develop initiate or complete preclinical studies and clinical trials for obtain approvals for and commercialize any of its product candidates changes in ignytas plans to develop and commercialize its product candidates the potential for final results of the ongoing clinical trials of entrectinib and our other product candidates or any future clinical trials of entrectinib and our other product candidates to differ from preliminary or expected results ignytas ability to raise any additional funding it will need to continue to pursue its business and product development plans regulatory developments in the united states and foreign countries ignytas ability to obtain and maintain intellectual property protection for its product candidates the risk that orphan drug exclusivity may not effectively protect a product from competition and that such exclusivity may not be maintained the potential for ignyta to fail to maintain the cap accreditation and clia certification of its diagnostic laboratory the loss of key scientific or management personnel competition in the industry in which ignyta operates and market conditions these forwardlooking statements are made as of the date of this press release and ignyta assumes no obligation to update the forwardlooking statements or to update the reasons why actual results could differ from those projected in the forwardlooking statements investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ignyta files with the sec available at wwwsecgov including without limitation ignytas annual report on form k for the year ended december   and subsequent quarterly reports on form q   ignyta inc jacob chacko md cfo  jcignytacom source ignyta inc did you like this article share this article twitter facebook google digg email print   related newsignyta boosts leadership capacity with appointment of bernard parker as chief commercial officerignyta appoints william mccarthy as chief business officeragendia board of directors appoints mark r straley as new chief executive officersteven c miller named chief commercialization officer at senior scientific subsidiary of manhattan scientificsprevencio appoints h perry fell phd as board chairman and rhonda f rhyne as president chief executive officer and board director reference articlesignyta appoints steven l hoerter chief commercial officer of agios pharmaceuticals inc to board of directors  business wire recent reports effective sales and marketing strategies for drugs with companion diagnostics ref firstword dossierpatientcentricity solving the latest pharma puzzle ref firstword dossierbiosimilar defensive plays – assessing the options ref firstword dossier about firstword medtech  refer a colleague  upgrade your firstword medtech  contact firstword medtech  firstword reportsadvertise with firstword medtech  industry partner showcaseall contents copyright   doctors guide publishing limited all rights reservedterms of use  privacy policy ignyta appoints steven l hoerter chief commercial officer of agios pharmaceuticals inc to board of directors press releasesnewscareerscontact twitterlinkedinyoutube homeabout usabout us overviewvision  valuesignyta’s storymanagementboard of directorsscientific advisory boardpipelinepatientspatients overviewwhat is precision medicinecancer clinical trialspatient storiespatient resourcesprovidersproviders overviewthe rxdx advantagerx – precision medicine pipelineentrectinibntrk fusionsros fusionsalk fusionsret fusionspantam inhibitorsdx – molecular diagnosticstrailblaze pharos™ignyta clinical trialsscientific presentationsinvestorsinvestors overviewpress releasesevents  presentationssec filingscorporate governancestock informationemail alerts ignyta press release article tj swing t sep   location source back to press releasesinvestor menuinvestors overview press releases events  presentations sec filings corporate governance stock information email alerts ignyta appoints steven l hoerter chief commercial officer of agios pharmaceuticals inc to board of directorshomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets closedsp  dow  nasdaq listenwho is the face of pro baseballyahoo finances dan roberts and myles udland debate the business of baseballignyta appoints steven l hoerter chief commercial officer of agios pharmaceuticals inc to board of directorsbusiness wiredecember  reblogsharetweetsharesan diegobusiness wireignyta inc rxdx a biotechnology company focused on precision medicine in oncology today announced the appointment of mr steven l hoerter to its board of directors effective december   mr hoerter will serve as an independent director as well as a member of the nominating and corporate governance committee the appointment increases the number of ignyta directors from five to six“steves extensive background in commercial strategy and operations complements the skillset of our existing board of directors very nicely and we are thrilled to welcome him to ignyta’s board” said jonathan lim md chairman and ceo of ignyta “we expect that his broad experience launching new oncology medicines will be an invaluable resource as ignyta seeks to transition into a fully integrated commercial organization”mr hoerter has served as chief commercial officer of agios pharmaceuticals inc since february  and has more than  years of global pharmaceutical and biotechnology experience previously having served as executive vice president and chief commercial officer at clovis oncology inc there mr hoerter built and led the global commercial organization that developed gotomarket strategies for two oncology therapies before joining clovis in  he was general manager and management center head at roche for the subsaharan africa and indian ocean region from  to  mr hoerter held a variety of positions at genentech inc including serving on the senior leadership team for genentech’s biooncology business as senior director pipeline development and commercial operations prior to that mr hoerter held commercial roles at chiron corporation and eli lilly and company in the us europe and africa mr hoerter received his ba from bucknell university mba from tilburg university and ms in management from purdue universitymr hoerter commented “i’m excited by ignyta’s robust precision oncology pipeline its strong team and outstanding commitment to helping patients with cancer i look forward to helping guide ignyta as it advances towards commercialization of its first product candidate”about ignyta incblazing a new future for patients with cancer™at ignyta we work tirelessly on behalf of patients with cancer to offer potentially lifesaving precisely targeted therapeutics rx guided by companion diagnostic dx tests our integrated rxdx strategy allows us to enter uncharted territory illuminating the molecular drivers of cancer and quickly advancing treatments to address them this approach embraces even those patients with the rarest cancers who have the highest unmet need and who may otherwise not have access to effective treatment options with our pipeline of potentially firstinclass and bestinclass precision medicines we are pursuing the ultimate goal of not just shrinking tumors but eradicating cancer relapse and recurrence in precisely defined patient populationsfor more information please visit wwwignytacomforwardlooking statementsthis press release contains forwardlooking statements about ignyta as that term is defined in section a of the securities act of  and section e of the securities exchange act of  statements in this press release that are not purely historical are forwardlooking statements such forwardlooking statements include among other things references to mr hoerter’s potential contributions and the development of ignytas product candidates actual results could differ from those projected in any forwardlooking statements due to numerous factors such factors include among others the inherent uncertainties associated with developing new products or technologies and operating as a development stage company ignytas ability to develop initiate or complete preclinical studies and clinical trials for obtain approvals for and commercialize any of its product candidates changes in ignytas plans to develop and commercialize its product candidates the potential for final results of the ongoing clinical trials of entrectinib and our other product candidates or any future clinical trials of entrectinib and our other product candidates to differ from preliminary or expected results ignytas ability to raise any additional funding it will need to continue to pursue its business and product development plans regulatory developments in the united states and foreign countries ignytas ability to obtain and maintain intellectual property protection for its product candidates the risk that orphan drug exclusivity may not effectively protect a product from competition and that such exclusivity may not be maintained the potential for ignyta to fail to maintain the cap accreditation and clia certification of its diagnostic laboratory the loss of key scientific or management personnel competition in the industry in which ignyta operates and market conditions these forwardlooking statements are made as of the date of this press release and ignyta assumes no obligation to update the forwardlooking statements or to update the reasons why actual results could differ from those projected in the forwardlooking statements investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ignyta files with the sec available at wwwsecgov including without limitation ignytas annual report on form k for the year ended december   and subsequent quarterly reports on form qview source version on businesswirecom httpwwwbusinesswirecomnewshomeenreblogsharetweetsharerecently viewedyour list is emptywhat to read nextthe two pizza rule is a secret to productive meetings that helped amazon ceo jeff bezos become one of the worlds richest menbusiness insiderthis will be in everyones household by banyan hillsponsoredhere are the us targets north korea most likely wants to nukebusiness insiderthe real reason overseas manufacturing is coming to americayahoo financechevron and exxon mobil have a tough path ahead nyse traderyahoo finance videoengineer finds pattern makes millions in stocksmoney morningsponsoredstocks mixed after heavy earnings weekapnewsbreak yellowstone park cracks down on sex harassmentassociated presstrump to cops please dont be too nice while arresting thugs and dont worry about their heads when you toss them in the paddy wagonbusiness insiderdiscover it  out of  avg by k customersdiscover cardsponsoredwells fargo faces angry questions after new sales abuses uncoveredreutersmy bullish view on stocks hasnt changed one iota nyse traderyahoo finance videoblue apron bullish calls not all theyre cooked up to bewhats the problem with joel osteenchurchleaderscomsponsoredjohn mccain heres why i voted no and killed the skinny repealbusiness insidera major player in the struggle for control of the sinaloa cartel just surrendered in the usbusiness insiderstruggling to govern trump faces growing republican uneasestuart actually this is the best our country can do right now if the republicans accomplished anything it would be tax cuts for the wealthy cuts to medicaid medicare and social security removal of all banking regulations and environmental protections and on and on get rid of these traitors in  so our country can be great againjoin the conversation  k